Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes

Aoyama, Koji

doi:10.1007/978-3-319-56015-1_217-1

Koji Aoyama⁶

203 Accesses

Abstract

Current strategies for the treatment of Parkinson’s disease (PD) are still mainly based on the use of dopaminergic medications such as l-dihydroxyphenylalanine (l-DOPA) and dopamine agonists to stimulate striatal dopamine receptors. Indeed, therapeutic intervention with these drugs has improved the prognosis of patients with PD over the last 50 years. However, it is still inconclusive as to which medication is the best for the initial treatment of PD and whether these medications have disease-modifying effects in the long clinical course of PD. In addition, long-term treatment with these drugs can cause complications that induce motor and non-motor symptoms, including withdrawal syndrome, in patients with PD. These symptoms are refractory to l-DOPA therapy and dominate the late-stage disability, which features some clinical milestones to the end of the disease. It is important to consider the influences of parkinsonian drug treatments on the clinical course of PD. In this chapter, therapy with parkinsonian drugs and their pharmacological properties, including adverse effects and influence on disease progression, will be discussed in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

Abrams WB, Coutinho CB, Leon AS, Spiegel HE. Absorption and metabolism of levodopa. JAMA. 1971;218:1912–4. https://www.ncbi.nlm.nih.gov/pubmed/5171067
Article CAS Google Scholar
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58. https://www.ncbi.nlm.nih.gov/pubmed/11391738
Article CAS Google Scholar
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366–75. https://www.ncbi.nlm.nih.gov/pubmed/2479133
Article CAS Google Scholar
Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–9. https://doi.org/10.1016/S1474-4422(07)70218-1.
Article CAS PubMed Google Scholar
Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2013;84:674–80. https://doi.org/10.1136/jnnp-2012-303135.
Article PubMed Google Scholar
Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577–88. https://doi.org/10.1038/35086062.
Article CAS PubMed Google Scholar
Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50:5848–52. https://doi.org/10.1021/jm070677y.
Article CAS PubMed Google Scholar
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA. 1999;96:12079–84. https://www.ncbi.nlm.nih.gov/pubmed/10518579
Article CAS Google Scholar
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29:1273–80. https://doi.org/10.1002/mds.25961.
Article CAS PubMed Google Scholar
Braak H, Del Tredici K. Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916–25. https://doi.org/10.1212/01.wnl.0000312279.49272.9f.
Article PubMed Google Scholar
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211. http://www.ncbi.nlm.nih.gov/pubmed/12498954
Article Google Scholar
Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18:733–46. https://www.ncbi.nlm.nih.gov/pubmed/15330687
Article CAS Google Scholar
Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol. 2008;75:63–75. https://doi.org/10.1016/j.bcp.2007.06.043.
Article CAS PubMed Google Scholar
Brown JH, Laiken N. Muscarinic agonists and antagonists. In: Brunton LL, editor. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw Hill Medical; 2011. p. 219–37.
Google Scholar
Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67:S18–23. https://doi.org/10.1212/wnl.67.7_suppl_2.s18.
Article CAS PubMed Google Scholar
Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson’s disease. Neurobiol Dis. 2003;14:404–16. https://www.ncbi.nlm.nih.gov/pubmed/14678757
Article CAS Google Scholar
Cattaneo C, Sardina M, Bonizzoni E. Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease fluctuating patients: post hoc analyses of studies 016 and SETTLE. J Park Dis. 2016;6:165–73. https://doi.org/10.3233/JPD-150700.
Article CAS Google Scholar
Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494–9. https://doi.org/10.1212/WNL.0b013e3181ec7fac.
Article CAS PubMed PubMed Central Google Scholar
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670–83. https://doi.org/10.1001/jama.2014.3654.
Article CAS PubMed Google Scholar
Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257:S253–61. https://doi.org/10.1007/s00415-010-5728-8.
Article CAS PubMed Google Scholar
Da Prada M, Kettler R, Zurcher G, Schaffner R, Haefely WE. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol. 1987;27(Suppl 1):9–20. http://www.ncbi.nlm.nih.gov/pubmed/3123242
Article CAS Google Scholar
Dairman W, Udenfriend S. Decrease in adrenal tyrosine hydroxylase and increase in norepinephrine synthesis in rats given l-dopa. Science. 1971;171:1022–4. https://www.ncbi.nlm.nih.gov/pubmed/5542806
Article CAS Google Scholar
Dairman W, Christenson JG, Udenfriend S. Decrease in liver aromatic l-amino-acid decarboxylase produced by chronic administration of l-dopa. Proc Natl Acad Sci USA. 1971;68:2117–20. https://www.ncbi.nlm.nih.gov/pubmed/5289371
Article CAS Google Scholar
de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001;49:298–303. https://www.ncbi.nlm.nih.gov/pubmed/11261503
De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 2017;74:970–6. https://doi.org/10.1001/jamaneurol.2017.1125.
Article PubMed PubMed Central Google Scholar
Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413–26. https://www.ncbi.nlm.nih.gov/pubmed/12030260
Article Google Scholar
Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–44. https://doi.org/10.1016/j.freeradbiomed.2013.01.018.
Article CAS PubMed Google Scholar
Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–44. https://www.ncbi.nlm.nih.gov/pubmed/3399075
Article CAS Google Scholar
El Atifi-Borel M, Buggia-Prevot V, Platet N, Benabid AL, Berger F, Sgambato-Faure V. De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. Neurobiol Dis. 2009;34:340–50. https://doi.org/10.1016/j.nbd.2009.02.002.
Article CAS PubMed Google Scholar
Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol. 1987;21:370–6. https://doi.org/10.1002/ana.410210409.
Article CAS PubMed Google Scholar
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22:1379–89; quiz 523. https://doi.org/10.1002/mds.21475.
Article PubMed Google Scholar
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508. https://doi.org/10.1056/NEJMoa033447.
Article CAS PubMed Google Scholar
Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283–301. https://www.ncbi.nlm.nih.gov/pubmed/1933245
Article Google Scholar
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–65. https://doi.org/10.1016/S1474-4422(15)00336-1.
Article CAS PubMed Google Scholar
Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003;304:498–506. https://doi.org/10.1124/jpet.102.042846.
Article CAS PubMed Google Scholar
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83. https://doi.org/10.1111/j.1532-5415.2011.03491.x.
Article PubMed Google Scholar
Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology. 1987;37:940–4. https://www.ncbi.nlm.nih.gov/pubmed/3587644
Article CAS Google Scholar
Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250:1429–32. https://www.ncbi.nlm.nih.gov/pubmed/2147780
Article CAS Google Scholar
Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature. 1977;265:80–1. https://www.ncbi.nlm.nih.gov/pubmed/834248
Article CAS Google Scholar
Godwin-Austen RB, Tomlinson EB, Frears CC, Kok HW. Effects of l-dopa in Parkinson’s disease. Lancet. 1969;2:165–8. https://www.ncbi.nlm.nih.gov/pubmed/4183130
Article Google Scholar
Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27:135–206. https://www.ncbi.nlm.nih.gov/pubmed/1103160
Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999;20:60–80. https://doi.org/10.1016/S0893-133X(98)00066-9.
Article CAS PubMed Google Scholar
Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014;137:2493–508. https://doi.org/10.1093/brain/awu193.
Article PubMed Google Scholar
Harada T, Mitsuoka K, Kumagai R, Murata Y, Kaseda Y, Kamei H, et al. Clinical features of malignant syndrome in Parkinson’s disease and related neurological disorders. Parkinsonism Relat Disord. 2003;9(Suppl 1):S15–23. https://www.ncbi.nlm.nih.gov/pubmed/12735911
Article Google Scholar
Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson’s disease. Mov Disord. 2000;15:485–9. https://www.ncbi.nlm.nih.gov/pubmed/10830413
Article CAS Google Scholar
Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22:2409–17. https://doi.org/10.1002/mds.21743.
Article PubMed Google Scholar
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–44. https://doi.org/10.1002/mds.21956.
Article PubMed Google Scholar
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality, Neurology. 1967; 17:427–42. https://www.ncbi.nlm.nih.gov/pubmed/6067254
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–53. https://doi.org/10.1001/archneur.61.7.1044.
Article PubMed Google Scholar
Horowski R, Loschmann PA. Classical dopamine agonists. J Neural Transm (Vienna). 2019;126:449–54. https://doi.org/10.1007/s00702-019-01989-y.
Article CAS Google Scholar
Humpel M, Krause W, Hoyer GA, Wendt H, Pommerenke G. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. Eur J Drug Metab Pharmacokinet. 1984;9:347–57. https://doi.org/10.1007/BF03189685.
Article CAS PubMed Google Scholar
Ikebe S, Harada T, Hashimoto T, Kanazawa I, Kuno S, Mizuno Y, et al. Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003;9(Suppl 1):S47–9. https://www.ncbi.nlm.nih.gov/pubmed/12735915
Article Google Scholar
Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology. 1996;47:785–8. https://www.ncbi.nlm.nih.gov/pubmed/8797480
Article CAS Google Scholar
Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58:1611–5. https://www.ncbi.nlm.nih.gov/pubmed/11594919
Article CAS Google Scholar
Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64:676–82. https://doi.org/10.1001/archneur.64.5.676.
Article PubMed Google Scholar
Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna). 2019;126:933–95. https://doi.org/10.1007/s00702-019-02028-6.
Article Google Scholar
Jiang H, Huang J, Shen Y, Guo S, Wang L, Han C, et al. RBD and neurodegenerative diseases. Mol Neurobiol. 2017;54:2997–3006. https://doi.org/10.1007/s12035-016-9831-4.
Article CAS PubMed Google Scholar
Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003; CD003735. https://doi.org/10.1002/14651858.CD003735.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749–59. https://doi.org/10.1016/S1474-4422(18)30239-4.
Article CAS PubMed Google Scholar
Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133:1755–62. https://doi.org/10.1093/brain/awq059.
Article PubMed Google Scholar
Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005;20:322–34. https://doi.org/10.1002/mds.20325.
Article PubMed Google Scholar
Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol. 1989; 166:589–90. https://doi.org/10.1016/0014-2999(89)90384-1.
Article CAS PubMed Google Scholar
Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206:297–300. https://doi.org/10.1016/0922-4106(91)90113-v.
Article CAS PubMed Google Scholar
Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997;48:81–7. https://www.ncbi.nlm.nih.gov/pubmed/9008498
Article CAS Google Scholar
Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065–78. https://doi.org/10.1016/j.clinthera.2006.08.004.
Article CAS PubMed Google Scholar
Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001;57:1687–94. https://www.ncbi.nlm.nih.gov/pubmed/11706112
Article CAS Google Scholar
Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197–206. https://doi.org/10.1001/jamaneurol.2016.4703.
Article PubMed Google Scholar
Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979;29:1253–60. https://www.ncbi.nlm.nih.gov/pubmed/573405
Article CAS Google Scholar
LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262–7. https://doi.org/10.1212/01.wnl.0000259516.61938.bb.
Article CAS PubMed Google Scholar
Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9. https://doi.org/10.1212/01.wnl.0000256715.13907.d3.
Article CAS PubMed Google Scholar
Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 1985;313:656–9. https://doi.org/10.1056/NEJM198509123131103.
Article CAS PubMed Google Scholar
Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl. 1983;19:253–64. https://www.ncbi.nlm.nih.gov/pubmed/6583311
Morgan JP, Bianchine JR, Spiegel HE, Rivera-Calimlim L, Hersey RM. Metabolism of levodopa in patients with Parkinson’s disease. Radioactive and fluorometric assays. Arch Neurol. 1971;25:39–44. https://www.ncbi.nlm.nih.gov/pubmed/5146410
Article CAS Google Scholar
Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–50. https://doi.org/10.1002/mds.10473.
Article Google Scholar
Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 1992;42:339–43. https://www.ncbi.nlm.nih.gov/pubmed/1736162
Article CAS Google Scholar
Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem. 1964;239:2910–7. https://www.ncbi.nlm.nih.gov/pubmed/14216443
Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44:913–9. https://www.ncbi.nlm.nih.gov/pubmed/8190296
Article CAS Google Scholar
Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol. 1997;42:349–55. https://doi.org/10.1002/ana.410420311.
Article CAS PubMed Google Scholar
Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord. 2006;21:343–53. https://doi.org/10.1002/mds.20724.
Article PubMed Google Scholar
Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H, et al. Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology. 1998;51:825–30. https://doi.org/10.1212/wnl.51.3.825.
Article CAS PubMed Google Scholar
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361:1268–78. https://doi.org/10.1056/NEJMoa0809335.
Article CAS PubMed Google Scholar
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–9. https://doi.org/10.1016/S1474-4422(13)70293-X.
Article CAS PubMed Google Scholar
Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30:788–95. https://doi.org/10.1002/mds.26159.
Article CAS PubMed PubMed Central Google Scholar
Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200–6. https://doi.org/10.1212/01.wnl.0000204007.46190.54.
Article CAS PubMed Google Scholar
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83. https://doi.org/10.1056/NEJM199301213280305.
Article Google Scholar
PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205. https://doi.org/10.1016/S0140-6736(14)60683-8.
Article CAS Google Scholar
Pessoa RR, Moro A, Munhoz RP, Teive HAG, Lees AJ. Apomorphine in the treatment of Parkinson’s disease: a review. Arq Neuropsiquiatr. 2018;76:840–8. https://doi.org/10.1590/0004-282X20180140.
Article PubMed Google Scholar
Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Neurology. 1996;47:S146–52. https://www.ncbi.nlm.nih.gov/pubmed/8959983
Article Google Scholar
Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–55. https://www.ncbi.nlm.nih.gov/pubmed/11939936
Article CAS Google Scholar
Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl. 1995;46:97–105. https://www.ncbi.nlm.nih.gov/pubmed/8821045
Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67:58–63. https://doi.org/10.1001/archneurol.2009.294.
Article PubMed Google Scholar
Rangel-Barajas C, Coronel I, Floran B. Dopamine receptors and neurodegeneration. Aging Dis. 2015;6:349–68. https://doi.org/10.14336/AD.2015.0330.
Article PubMed PubMed Central Google Scholar
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–91. https://doi.org/10.1056/NEJM200005183422004.
Article CAS PubMed Google Scholar
Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, et al. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016;31:1489–96. https://doi.org/10.1002/mds.26724.
Article CAS PubMed Google Scholar
Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm. 1978;43:271–7. https://www.ncbi.nlm.nih.gov/pubmed/745019
Article CAS Google Scholar
Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem. 1986;46:1359–65. https://doi.org/10.1111/j.1471-4159.1986.tb01747.x.
Article CAS PubMed Google Scholar
Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, et al. alpha-Synuclein in Parkinson’s disease: causal or bystander? J Neural Transm (Vienna). 2019;126:815–40. https://doi.org/10.1007/s00702-019-02025-9.
Article Google Scholar
Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979;29:1584–9. https://www.ncbi.nlm.nih.gov/pubmed/574221
Article CAS Google Scholar
Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, et al. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016. https://doi.org/10.1111/ene.13034.
Article CAS Google Scholar
Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76:763–75. https://doi.org/10.1111/bcp.12081.
Article CAS PubMed PubMed Central Google Scholar
Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–73. https://doi.org/10.1002/ana.21291.
Article PubMed Google Scholar
Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12:747–55. https://doi.org/10.1016/S1474-4422(13)70117-0.
Article CAS PubMed PubMed Central Google Scholar
Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:73–86. https://doi.org/10.1007/s00210-008-0341-4.
Article CAS PubMed Google Scholar
Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46:388–93. https://www.ncbi.nlm.nih.gov/pubmed/8614500
Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123(Pt 11):2297–305. https://www.ncbi.nlm.nih.gov/pubmed/11050029
Article Google Scholar
Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–3. https://www.ncbi.nlm.nih.gov/pubmed/14913646
Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69:183–9. https://doi.org/10.1002/syn.21805.
Article CAS PubMed Google Scholar
Serrano-Duenas M. Neuroleptic malignant syndrome-like, or – dopaminergic malignant syndrome – due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175–8. https://www.ncbi.nlm.nih.gov/pubmed/12573874
Article Google Scholar
St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson’s disease and other synucleinopathies. Mov Disord. 2017;32:645–58. https://doi.org/10.1002/mds.27018.
Article CAS PubMed Google Scholar
Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain. 2002;125:2058–66. https://doi.org/10.1093/brain/awf214.
Article PubMed Google Scholar
Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746–8. https://doi.org/10.1212/01.wnl.0000134672.44217.f7.
Article CAS PubMed Google Scholar
Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62:905–10. https://doi.org/10.1001/archneur.62.6.905.
Article PubMed Google Scholar
Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27:106–12. https://doi.org/10.1002/mds.23954.
Article CAS PubMed Google Scholar
Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:141–3. https://www.ncbi.nlm.nih.gov/pubmed/14707325
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–6. https://www.ncbi.nlm.nih.gov/pubmed/9595981
Article CAS Google Scholar
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28:1064–71. https://doi.org/10.1002/mds.25364.
Article CAS PubMed Google Scholar
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–95. https://doi.org/10.1001/archneurol.2010.65.
Article PubMed Google Scholar
Weiss JL, Cohn CK, Chase TN. Reduction of catechol-O-methyl-transferases activity by chronic l-dopa therapy. Nature. 1971;234:218–9. https://www.ncbi.nlm.nih.gov/pubmed/4943087
Article CAS Google Scholar
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101. https://doi.org/10.1002/ana.10609.
Article CAS Google Scholar
Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4:605–10. https://doi.org/10.1016/S1474-4422(05)70146-0.
Article PubMed Google Scholar
Woitalla D, Muller T, Benz S, Horowski R, Przuntek H. Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl. 2004;68:89–95. https://www.ncbi.nlm.nih.gov/pubmed/15354393
Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect. 1993;91:181–95. https://www.ncbi.nlm.nih.gov/pubmed/8390270
Article CAS Google Scholar
Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: a comprehensive review. J Neurol Sci. 2017;374:53–5. https://doi.org/10.1016/j.jns.2016.12.070.
Article CAS PubMed Google Scholar
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46. https://doi.org/10.1056/NEJMoa054830.
Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

Department of Pharmacology, Teikyo University School of Medicine, Itabashi, Tokyo, Japan
Koji Aoyama

Authors

Koji Aoyama
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Aoyama .

Editor information

Editors and Affiliations

Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany
Peter Riederer
Inst für Psychologische Medizin, Haag, Bayern, Germany
Gerd Laux
Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada
Benoit Mulsant
Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China
Weidong Le
Fujita Health University School Medicine, Toyoake, Aichi, Japan
Toshiharu Nagatsu

Section Editor information

Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Toshiharu Nagatsu
Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan
Toshiharu Nagatsu
Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

About this entry

Cite this entry

Aoyama, K. (2020). Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_217-1

Download citation

DOI: https://doi.org/10.1007/978-3-319-56015-1_217-1
Received: 09 August 2019
Accepted: 07 October 2019
Published: 07 November 2019
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics